ARTICLE | Management Tracks
Plus: Noema hires Volker Knappertz as EVP of R&D, and updates from Lux, COA, Imbed and March Bio
By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
December 20, 2024 1:13 AM UTC
Neutrolis Inc. named Michael Fleming chief business and strategy officer, Andreas Reiff CMO, and Ralph Lambalot CTO. Fleming was president of a life sciences advisory firm, before which he was chief strategy officer of Coherus Biosciences Inc. (NASDAQ:CHRS). Reiff was SVP of immunology and inflammation at Parexel International Corp., and Lambalot was VP of operations science and technology at Abbvie Inc. (NYSE:ABBV). Neutrolis is developing therapies targeting neutrophil extracellular traps.
CNS disorders play Noema Pharma AG hired Volker Knappertz as EVP of R&D. Knappertz was EVP of R&D at Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654544/new-business-medical-and-technology-heads-at-neutrolis